Caixin
Feb 12, 2022 06:30 PM
TECH

China Approves Pfizer’s Covid-19 Treatment for Vulnerable Patients

China has given conditional approval for emergency use of U.S. pharmaceutical giant Pfizer Inc.’s Covid-19 antiviral medicine Paxlovid. Photo: IC Photo
China has given conditional approval for emergency use of U.S. pharmaceutical giant Pfizer Inc.’s Covid-19 antiviral medicine Paxlovid. Photo: IC Photo

China’s drug regulator has given conditional approval for emergency use of U.S. pharmaceutical giant Pfizer Inc.’s Covid-19 antiviral medicine Paxlovid, becoming the first oral treatment cleared to treat patients in the country as authorities continue to battle ongoing flare-ups of the coronavirus.

Paxlovid will be used to treat adults suffering mild-to-moderate Covid-19-induced pneumonia and who are at high risk of developing severe illness, especially those that have co-morbidities like diabetes and cardiovascular disease, the National Medical Products Administration (NMPA) said in a statement Saturday (link in Chinese).

You've accessed an article available only to subscribers
VIEW OPTIONS
Share this article
Open WeChat and scan the QR code
NEWSLETTERS
Get our CX Daily, weekly Must-Read and China Green Bulletin newsletters delivered free to your inbox, bringing you China's top headlines.

We ‘ve added you to our subscriber list.

Manage subscription